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Phase I Study of Two Different Schedules of Bortezomib
and Pemetrexed in Advanced Solid Tumors with Emphasis
on Non-small Cell Lung Cancer
Angela M. Davies, MD,* Cheryl Ho, MD,† Alex S. Metzger, MD,‡ Laurel A. Beckett, PhD,*
Scott Christensen, MD,* Michael Tanaka, MD,* Primo N. Lara, MD,* Derick H. Lau, MD, PhD,*
and David R. Gandara, MD*
Introduction: Bortezomib and pemetrexed are approved anticancer
agents with non-overlapping mechanisms of action and toxicity. We
examined the safety and tolerability of pemetrexed in combination
with two different schedules of bortezomib in patients with ad-
vanced solid tumors.
Methods: Two separate dose-escalating arms (arm A and arm B) were
conducted simultaneously. Patients received pemetrexed on day 1 (D1)
(500–600 mg/m2 IV) every 21 days. In arm A, bortezomib was given
twice weekly (0.7–1.3 mg/m2 on D1, 4, 8, and 11). In arm B, bort-
ezomib was given weekly (1.0–1.6 mg/m2 on D1 and 8).
Results: We treated 27 patients on four dose levels in arm A and
three dose levels in arm B. Tumor types included lung (n  16),
adenoid cystic carcinoma (n 2), prostate (n 2), sarcoma (n 2),
breast (n  1), thymus (n  1), head and neck (n  1), and
gastrointestinal(n  2). Dose-limiting toxicities were seen in arm A
only; grade 3 asthenia (n 2), grade 3 transaminitis and dehydration
(n  1). The most common grade 3/4 toxicity was neutropenia. Of
26 evaluable patients, 2 patients had partial response (1 in arm A and
1 in arm B), 13 had stable disease (7 in arm A and 6 in arm B), and
11 had progression (6 in arm A and 5 in arm B). Of the 16 patients
with non-small cell lung cancer, 2 (12.5%) had partial response and
9 had stable disease, for a disease control rate of 68.8%. Recom-
mended phase II dose for arm A is pemetrexed 500 mg/m2 and
bortezomib 1.3 mg/m2 twice weekly. For arm B, the recommended
dose is pemetrexed 500 mg/m2, bortezomib 1.6 mg/m2 weekly.
Conclusions: Pemetrexed with bortezomib is feasible and tolerable
at recommended single-agent doses. Based on the observed efficacy,
a phase II study in non-small cell lung cancer is warranted.
Key Words: Phase I, Bortezomib, Proteasome, Pemetrexed, Non-
small cell lung cancer.
(J Thorac Oncol. 2007;2: 1112–1116)
Bortezomib (PS-341), a potent and selective proteasomeinhibitor, targets the ubiquitin-proteasome pathway.1 It is
active as a single agent and potentiates chemotherapy and
radiation in preclinical models.2 Bortezomib is approved by
the Food and Drug Administration for the treatment of
second-line multiple myeloma and mantle cell lymphoma.
Early phase clinical studies have demonstrated tolerability
and activity in a variety of hematologic malignancies and
solid tumors. By its mechanism of inhibiting protein degra-
dation, bortezomib targets a wide range of pathways that are
relevant to tumor progression and therapy resistance and can
directly modulate expression of cyclins, p27Kip1, p53, NF-B,
Bcl-2, and Bax.3 Preclinical data suggest that proteasome
inhibition may reverse platinum resistance, which is a com-
mon cause of treatment failure and disease progression in
many solid tumors, although its mechanism is not known.4
Although bortezomib has shown its greatest benefit in
the treatment of relapsed multiple myeloma, it targets many
key cell cycle regulators that are relevant to tumor progres-
sion and therapy resistance in solid tumors like lung cancer.5,6
The ability of bortezomib to favorably modulate the expres-
sion of apoptosis-associated proteins, along with its moderate
toxicity as a single agent, provides the basis for its combina-
tion with cytotoxic agents.
Pemetrexed is a novel, multi-targeted antifolate that
inhibits at least three of the enzymes involved in folate
metabolism (thymidylate synthase, dihydrofolate reductase,
and glycinamide ribonucleotide formyltransferase) and pu-
rine and pyrimidine synthesis. Pemetrexed has demonstrated
broad anti-tumor activity in a wide variety of solid tumors.7
Its most significant toxicities include myelosuppression and
mucositis, although these toxicities have been significantly
reduced with supplementation of folate and vitamin B12
without affecting efficacy. Based on data from randomized
phase III trials, pemetrexed has been approved for use in
mesothelioma in combination with cisplatin and as a single
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agent in previously treated non-small cell lung cancer
(NSCLC).8,9
Bortezomib’s novel mechanism of action and efficacy
against a number of malignancies makes it an attractive agent
to be combined with another targeted agent like pemetrexed.
Bortezomib would be expected to synergize with chemother-
apy as a result of its ability to lower the apoptotic threshold
of cancer cells and has been empirically combined with
pemetrexed in this study. It is hypothesized that the combi-
nation of pemetrexed and bortezomib can be administered
safely in patients with advanced solid tumors without a
significant increase in toxicity.
PATIENTS AND METHODS
Patient Selection
Patients with histologically or cytologically diagnosed
advanced solid tumors were eligible. Other eligibility criteria
included: age older than 18 years, life expectancy longer than
12 weeks, performance status 0–2, and any number of prior
chemotherapy regimens. Adequate hematologic, renal, and
hepatic function were required. Patients with asymptomatic
treated brain metastasis were eligible for this trial if they were
neurologically stable and had been off steroids for at least 4
weeks. Because of possible bortezomib-related neurotoxicity,
patients with preexisting neuropathy grade 2 or greater were
not eligible to participate. Patients who had previously re-
ceived pemetrexed or bortezomib were excluded. If patients
were taking nonsteroidal antiinflammatories or salicylates,
they were required to stop the medication from the day before
until the day after receiving pemetrexed because of potential
interaction. The institutional review boards at University of
California Davis Campus and Veterans Affairs Contra Costa
Regional Medical Center approved this study. All patients
gave written informed consent.
Dose-Limiting Toxicity and Maximal Tolerated
Dose Definitions
A dose-limiting toxicity (DLT) was defined as any of
the following that occurred within the first cycle of treatment:
grade 4 thrombocytopenia or grade 3 thrombocytopenia as-
sociated with bleeding, requirement for transfusion, or lasting
longer than 7 days; febrile neutropenia; grade 3 neutropenia
associated with a documented infection; or any other grade 3
or greater non-hematologic toxicity considered by the inves-
tigator to be related to study drug. Toxicity was graded
according to the NCI Common Toxicity Criteria Adverse
Events (NCI CTCAE) V 3.0.
All patients treated at a particular dose level were
observed for a minimum of 21 days after the start of the first
course (i.e., the length of the treatment cycle) before accrual
to the next dose level was allowed. No intra-patient dose
escalation was allowed.
Patients were accrued in cohorts of three patients per
dose level. If none of the three patients experienced a DLT,
three patients were treated at the next dose level. If DLT
attributable to the treatment was experienced in one of three
patients, three more patients (for a total of six patients) were
treated at that dose level. If no additional DLT was observed
at the expanded dose level (i.e., one of six with DLT), the
dose was escalated. Escalation terminated as soon as two or
more patients experienced any DLT attributable to study
drugs at a given dose level.
The maximal tolerated dose (MTD) was defined as the
highest dose level at which no more than one patient expe-
rienced a DLT when at least six patients were treated at that
dose and were evaluable for toxicity or when the final dose
level was reached.
Treatment Plan
The treatment schema is represented in Table 1, and the
dose escalation scheme is summarized in Table 2. Patients were
treated on one of two treatment arms, A or B. Accrual to
treatment arm A was independent of accrual to treatment arm B.
In arm A, pemetrexed was administered intravenously
on day 1 of a 21-day cycle, and bortezomib was given
intravenously on day 1, 60 minutes after the pemetrexed
infusion, then on days 4, 8 and 11. In arm B, pemetrexed was
delivered intravenously on day 1 of a 21-day cycle, and
bortezomib was given intravenously on day 1, 60 minutes
after the pemetrexed infusion, then on day 8. All patients
received dexamethasone 4 mg orally twice daily for 3 days
starting the day before pemetrexed, vitamin B12 1000 ug
intramuscularly 1 week before starting treatment and every 9
weeks and folic acid 350 ug orally daily starting 5 to 7 days
before treatment, to prevent toxicities associated with pem-
etrexed. Treatment was continued in the absence of disease
progression, provided that patients were clinically benefiting
and were tolerating the treatment.
Patient Assessments
Before each cycle, patients had a medical history taken
and physical examination. Weekly complete blood counts
including white blood cell differential were performed. Se-
rum chemistry including electrolytes; creatinine and liver
function tests were performed every 3 weeks. Intercurrent
toxicities were assessed before each cycle using the NCI
CTCAE V 3.0. Response to therapy was evaluated every two
cycles according to the RECIST criteria.
RESULTS
Twenty-seven patients with advanced solid tumors
were enrolled in this two-arm phase I trial. Patient character-
istics are listed in Table 3. The median age was 60 years, and
most patients had a good performance status. The median
number of prior chemotherapy regimens was two; only two
TABLE 1. Treatment Schema
Arm A Day 1 Day 4 Day 8 Day 11 Day 22
Pemetrexed X X
Bortezomib X X X X X
Arm B Day 1 Day 8 Day 22
Pemetrexed X X
Bortezomib X X X
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chemo-naı¨ve patients were enrolled in the trial. The most
common tumor type was NSCLC (59%).
Dose-Limiting Toxicity
In arm A (pemetrexed on day 1 and bortezomib days 1,
4, 8, and 11 every 21 days), no DLTs were observed in three
patients enrolled on both dose level 1 and level 2. Three
patients were initially enrolled on dose level 3 with no DLTs,
and the dose was escalated to dose level 4. Two of three
patients on dose level 4 developed grade 3 asthenia. Thus, an
additional three patients were treated on dose level 3, and one
developed transaminitis (grade 3) and dehydration (grade 3)
requiring intravenous fluids (see Table 2).
In arm B (pemetrexed on day 1 and bortezomib days 1
and 8 every 21 days), no DLTs were observed in dose levels
1 through 3. There had initially been a dose level 4 (pem-
etrexed 600 mg/m2 and bortezomib 1.6 mg/m2 days 1 and 8),
but the protocol was amended because of the toxicity data
from arm A at this dose of pemetrexed. Six patients were
treated at dose level 3 with no DLTs.
Toxicities
Treatment was generally well tolerated. There were no
treatment-related deaths. Clinically significant hematologic
toxicities were limited (Table 4). Grade 3/4 neutropenia was
seen in 12 of 15 patients in arm A and 1 of 12 patients in arm
B. Grade 3 anemia was observed in one patient in arm A.
There were no episodes of febrile neutropenia or significant
bleeding in any patient. Grade 3 non-hematologic toxicities in
arm A included one patient with increased transaminases and
two patients with fatigue. In arm B, there was one patient with
grade 3 weakness. Low-grade transaminitis, renal dysfunction,
nausea, and vomiting were also observed more commonly with
biweekly dosing. Other common non-hematologic toxicities are
outlined in Table 5.
Recommended Phase II Dose
Based on these findings, the recommended dose in arm
A is pemetrexed 500 mg/m2 on day 1 and bortezomib 1.3
mg/m2 on days 1, 4, 8, and 11 every 3 weeks. In arm B, the
recommended dose is pemetrexed 500 mg/m2 on day 1 and
bortezomib 1.6 mg/m2 on days 1 and 8 every 21 days. These
doses reflect the recommended dosing for both agents when
used as single agents in the same schedule. Therefore, the
combination requires no dose modification of either drug.
Anti-Tumor Activity
In arm A, there was one patient with a partial response
with stage IV NSCLC at dose level 1. He had previously been
TABLE 2. Dose Escalation and Dose-limiting Toxicities
Level
Pemetrexed
(mg/m2)
Bortezomib
(mg/m2) Patients (n) DLT DLT Description
Twice Weekly
Arm A
1 500 0.7 3 0
2 500 1 3 0
3 500 1.3 6 1 Transaminitis, dehydration
4 600 1.3 3 2 Grade 3 asthenia both patients
Once Weekly
Arm B
1 500 1 3 0
2 500 1.3 3 0
3 500 1.6 6 0
DLT, dose-limiting toxicity.
TABLE 3. Baseline Patient Characteristics
Patient Characteristics
Patients 27
Sex (male/female) 15/12
Age (yr) 60 (39–80)
KPS (90/80) 15/12
Prior regimens 2 (0–6)
Tumor type
NSCLC 16
Adenoid cystic carcinoma 2
GI 2
Prostate 2
Sarcoma 2
Breast 1
Head and neck 1
Thymus 1
Data are expressed as n or median (range). KPS, Karnofsky performance status;
NSCLC, non-small cell lung cancer; GI, gastrointestinal.
TABLE 4. Hematologic Adverse Events Possibly Related to
Treatment
Hematologic Toxicity Grade >3 Arm A Arm B
Neutropeniaa 12 1
Anemia 1 0
Thrombocytopenia 0 1
a There were no episodes of febrile neutropenia.
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treated with four chemotherapy regimens including gemcit-
abine/carboplatin for six cycles, on clinical trial with pertu-
zumab, a novel antibody inhibitor of HER dimerization for
four cycles, gefitinib for 3 months, and docetaxel for three
cycles. He received a total of 15 cycles and came off the trial
without progression by investigators’ choice. Seven patients
had stable disease (four NSCLC, one thymic carcinoma, one
prostate carcinoma, one adenoid cystic carcinoma) and the
remainder progressed. Among the four patients with NSCLC
with stable disease, the duration was 5, 9.7, 5.2, and 2.5
months.
In arm B, one patient with stage IV NSCLC had a
partial response at dose level 3. She had been treated with one
prior chemotherapy regimen, carboplatin/paclitaxel for four
cycles, followed by cetuximab for 2.5 months on a clinical
trial. She received four cycles of pemetrexed and bortezomib
and came off of therapy because of atrial fibrillation, deep
venous thrombosis, and pulmonary embolus not believed to
be related to the study medication. Six patients had stable
disease (five NSCLC, one adenoid cystic carcinoma) and five
progressed. Among the five patients with NSCLC with stable
disease, the duration was 6.4, 2.3, 12.1, 2.8, and 5.9 months.
DISCUSSION
This is the first reported trial combining bortezomib and
pemetrexed. This phase I trial was conducted to determine the
safety and feasibility of combining pemetrexed and two
different schedules of bortezomib. Both schedules of bort-
ezomib and pemetrexed were well tolerated and were able to
be administered at recommended single-agent doses. Higher
rates of grade 3/4 neutropenia were seen with the twice-
weekly bortezomib; however, none of the patients developed
febrile neutropenia. Low-grade transaminitis, renal dysfunc-
tion, nausea, and vomiting were also observed more com-
monly with twice weekly dosing, potentially related to the
increased total dose of bortezomib.
The feasibility of this combination was evaluated for
further development of the combination in a phase II second-
line advanced NSCLC trial. Pemetrexed is well established as
a therapy in patients with NSCLC. In a large randomized
phase III trial, pemetrexed with B12 and folate supplemen-
tation was compared with standard second-line docetaxel in
patients with previously treated NSCLC.9 Whereas efficacy
was similar, there was less myelosuppression with pem-
etrexed. Bortezomib has been evaluated in first- and second-
line therapy in combination with chemotherapy in advanced
NSCLC. A phase II Southwest Oncology Group study
(S0339) evaluated bortezomib in combination with carbopla-
tin/gemcitabine in the first-line setting and demonstrated
encouraging results with a response rate of 21%, stable
disease rate of 45%, and a median survival of 11 months.10,11
Predictive markers for bortezomib efficacy remain elu-
sive and an area of ongoing research.12,13 Although change in
alkaline phosphatase, a marker for osteolytic destruction,
from baseline in patients with multiple myeloma was predic-
tive for treatment response and time to progression, it is
unlikely to be a reliable predictor in solid tumors.14
Our study demonstrates that the combination of pem-
etrexed and bortezomib is feasible and well tolerated in an
advanced solid tumor population. In previous solid tumor studies
combining chemotherapy with bortezomib, dose escalation has
been limited primarily by myelosuppression. Pemetrexed can be
delivered at the standard single-agent dose even when given in
combination with bortezomib, possibly because it causes com-
paratively less myelosuppression than other chemotherapeutic
agents. The twice-weekly bortezomib regimen in combination
with pemetrexed, however, was associated with more neutrope-
nia. The once-weekly regimen seems to have similar efficacy to
the twice-weekly regimen and provides a more convenient
dosing schedule. Based on its tolerability and preliminary effi-
cacy in NSCLC, a phase II study of pemetrexed in combination
with weekly bortezomib is warranted.
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